Treatment Options Differ for Patients With Benign or Malignant Thyroid Cancer
Winston Tan, MD, discusses the current treatment landscape for patients with thyroid cancer. He highlighted the importance of first determining if a patient with thyroid cancer has benign or malignant thyroid nodules, which can be identified with the use of diagnostic biopsies. He also discussed the standard-of-care treatment options for these different subtypes of patients once they are identified.
Winston Tan, MD, a hematologist/oncologist at the Mayo Clinic and vice president of the Florida Society for Clinical Oncology (FLASCO), discusses the current treatment landscape for patients with thyroid cancer. He highlighted the importance of first determining if a patient with thyroid cancer has benign or malignant thyroid nodules, which can be identified with the use of diagnostic biopsies. He also discussed the standard-of-care treatment options for these different subtypes of patients once they are identified.
The primary treatment for patients with thyroid cancer is surgery, Tan says. For patients that are diagnosed with benign and localized disease, they can receive a thyroidectomy. However, for patients with locally advanced thyroid cancer, it is appropriate to combine surgery with a radioactive iodine treatment.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
Post Hoc and Real-World Analyses Explore Benefit of Lenvatinib in DTC
December 5th 2024During a Case-Based Roundtable® event, Lori J. Wirth, discussed recent analyses that have developed a better understanding of the outcomes with lenvatinib in differentiated thyroid cancer in the second article of a 2-part series.
Read More
